A CARRIER-MEDIATED TRANSPORT OF TOXINS IN A HYBRID MEMBRANE. SAFETY BARRIER BETWEEN A PATIENTS BLOOD AND A BIOARTIFICIAL LIVER
作者： J. Stange , S. Mitzner
DOI: 10.1177/039139889601901109
关键词: Transport protein 、 Biomedical engineering 、 Membrane 、 In vivo 、 Chemistry 、 Membrane transport protein 、 Bioartificial liver device 、 Liver support systems 、 Albumin 、 Biophysics 、 Liver cell
摘要: Combination of detoxifying liver support systems with cell bioreactors may have additional benefits for the treatment failure due to replacement known and unknown metabolic activities liver. However, problem side effects possible risks caused by use animal hepatocytes or hepatoma cells remains unsolved which underlines need a safety barrier between patients blood extracorporeal bioreactor. Passive filters do not meet requirements such membranes, because in desired undesired molecules share similar physicochemical properties. That challenges development biologically designed separation membranes. A hybrid membrane is formed implementation transport proteins into highly permeable hollow fiber. The free solutes albumin bound toxins tested vitro comparison conventional high flux characteristics tightly are significantly improved membrane. across associated albumin. selectivity evaluated vivo. No significant loss middle molecular weight hormones attached other carrier was observed. Neither immunologically relevant nor valuable measured. Also vivo, reduction protein metabolically solutes, like amino acids, shown. presented be used an "intelligent membrane" as devices.
sagepub.com
sci-hub.se 参考文章(24)
Rory P. Remmel, Madhusudan V. Peshwa, Henry J. Mann, Scott L. Nyberg, Wei Shou Hu, Frank B. Cerra, Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver Annals of Surgery. ,vol. 220, pp. 59- 67 ,(1994)
M. Höhne, S. Schaefer, M. Seifer, M.A. Feitelson, D. Paul, W.H. Gerlich, Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatitis B virus DNA. The EMBO Journal. ,vol. 9, pp. 1137- 1145 ,(1990) , 10.1002/J.1460-2075.1990.TB08220.X
David Seligson, Jean Marino, Elizabeth Dodson, Determination of Sulfobromophthalein in Serum Clinical Chemistry. ,vol. 3, pp. 638- 645 ,(1957) , 10.1093/CLINCHEM/3.5.638
Achilles A. Demetriou, Andrew Reisner, Jay Sanchez, Stanley M. Levenson, Albert D. Moscioni, J. Roy Chowdhury, Transplantation of microcarrier-attached hepatocytes into 90% partially hepatectomized rats. Hepatology. ,vol. 8, pp. 1006- 1009 ,(1988) , 10.1002/HEP.1840080505
Sien-Sing Yang, Jacob Korula, James E. Sundheimer, Anthony J. Keyser, Digoxin‐like immunoreactive substances in chronic liver disease Hepatology. ,vol. 9, pp. 363- 366 ,(1989) , 10.1002/HEP.1840090304
Mark S. Cattral, Gary A. Levy, Artificial Liver Support -- Pipe Dream or Reality? New England Journal of Medicine. ,vol. 331, pp. 268- 269 ,(1994) , 10.1056/NEJM199407283310411
Anthony S. Basile, Phil M. Harrison, Robin D. Hughes, Zi-Quang Gu, Lewis Pannell, Angelique McKinney, E. Anthony Jones, Roger Williams, Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hepatology. ,vol. 19, pp. 112- 121 ,(1994) , 10.1002/HEP.1840190119
Hugo O. Jauregui, Claudy J-P. Mullon, Donna Trenkler, Sharda Naik, Henry Santangini, Philip Press, Thomas E. Muller, Barry A. Solomon, In vivo evaluation of a hollow fiber liver assist device Hepatology. ,vol. 21, pp. 460- 469 ,(1995) , 10.1002/HEP.1840210230
Hugo O. Jauregui, Kathryn L. Gann, Mammalian hepatocytes as a foundation for treatment in human liver failure. Journal of Cellular Biochemistry. ,vol. 45, pp. 359- 365 ,(1991) , 10.1002/JCB.240450409
J. Stange, W. Ramlow, S. Mitzner, R. Schmidt, H. Klinkmann, Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artificial Organs. ,vol. 17, pp. 809- 813 ,(2008) , 10.1111/J.1525-1594.1993.TB00635.X